Phase 2 Study of Disease Risk Mutation-Guided Finite Acalabrutinib+Venetoclax for Relapsed CLL Post-1L Finite cBTKi+BCL2i ± Obinutuzumab
Recruiting now · Phase 2
Conditions studied: Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)
In brief
This study will evaluate the efficacy and safety of finite-duration acalabrutinib plus venetoclax therapy in patients with relapsed CLL or SLL, and have previously responded to first line (1L) cBTKi + BCL2i therapy (± obinutuzumab) and maintained a response for at least two years post-treatment.
Key facts
- Study ID
- NCT07024706
- Run by
- AstraZeneca
- People needed
- 80
- Starts
- 2026-06-04
- Expected to finish
- 2033-03-23
- Last updated by the study team
- 2026-08-06
Who can join
Age: 18 and older, up to 130. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Research Site — Boston, Massachusetts, United States (enrolling)
- Research Site — Charlotte, North Carolina, United States (enrolling)
- Research Site — Durham, North Carolina, United States (enrolling)
- Research Site — Winston-Salem, North Carolina, United States (enrolling)
- Research Site — Horn, Austria (enrolling)
- Research Site — Dublin, Ireland (enrolling)
- Research Site — Dublin, Ireland (enrolling)
- Research Site — Meldola, Italy (enrolling)
- Research Site — Padua, Italy (enrolling)
- Research Site — Ravenna, Italy (enrolling)
- Research Site — Barcelona, Spain (enrolling)
- Research Site — Granada, Spain (enrolling)
- Research Site — Madrid, Spain (enrolling)
- Research Site — Madrid, Spain (enrolling)
- Research Site — Majadahonda, Spain (enrolling)
- Research Site — Warsaw, Poland
- Research Site — Warsaw, Poland
- Research Site — Milan, Italy
- Research Site — Milan, Italy
- Research Site — Madrid, Spain
- Research Site — Barcelona, Spain
- Research Site — Rome, Italy
- Research Site — Charlotte, North Carolina, United States
- Research Site — Torino, Italy
- Research Site — Bydgoszcz, Poland
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.